Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;5(23):465.
doi: 10.21037/atm.2017.09.19.

Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction

Ahsan A Khan  1 , Gregory Y H Lip  1   2
Affiliations
Editorial

Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction

Ahsan A Khan et al. Ann Transl Med. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Professor Lip has served as a consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Daiichi-Sankyo; and a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo. No personal fees received. AA Khan has no conflicts of interest to declare.

Comment on

References

    1. Lip G, Freedman B, De Caterina R, et al. Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost 2017;117:1230-9. 10.1160/TH16-11-0876 - DOI - PubMed
    1. Skjøth F, Larsen TB, Rasmussen LH, et al. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014;111:981-8. 10.1160/TH14-02-0118 - DOI - PubMed
    1. Blann AD, Skjoth F, Rasmussen LH, et al. Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2015;114:403-9. 10.1160/TH15-05-0383 - DOI - PubMed
    1. Lip GY, Fauchier L, Freedman SB, et al. Atrial fibrillation. Nat Rev Dis Primers 2016;2:16016. 10.1038/nrdp.2016.16 - DOI - PubMed
    1. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-507. 10.1093/europace/euv309 - DOI - PubMed

LinkOut - more resources